This microsite provides a simplified overview on the Fresenius Performance Plan 2023 without obligation. Please note that only the plan terms (German version) are legally binding. These plan terms, together with the regularly updated Information Paper (both available on EquatePlus), include further information about the details of the Plan.
Please note that your participation in the Fresenius Performance Plan 2023 create, and also should not be read or interpreted so as to create, a legal entitlement to continue to be granted virtual stock awards and/or a certain grant value in the future. Any decision as to the granting of virtual stock awards and/or the allocation of particular grant values to you is subject to the sole discretion of the Management Board of the Company’s General Partner, to be determined on a case-by case basis.
This microsite contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic, and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this microsite.
It is strictly forbidden to trade shares exploiting insider knowledge. Please be aware of the legal regulations on insider trading of each country.